TITLE

D01 Updating of guidelines for the molecular genetic predictive test in Huntington's disease (1994)

AUTHOR(S)
MacLeod, R; Tibben, A; Frontali, M
PUB. DATE
September 2010
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background Guidelines for the molecular genetic predictive testing in Huntington's disease (HD) were issued in 1994, soon after the discovery of the gene. Since then, the research on HD has made remarkable advancements and a considerable amount of experience was acquired by centres offering the presymptomatic and prenatal HD tests. After 16 years the EHDN WG on Genetic Testing and Counselling thought that some recommendations should be updated and some added, on the basis of scientific evidence and documents collected so far. Methods WG participants, including members of the lay association, psychologists, neurologists, geneticists, genetic counsellors and ethicists from all over Europe were divided into subgroups, each devoted to a particular topic. Each subgroup had to collect the relevant scientific literature and documents, discuss the possible changes and propose an update. The updates proposed by each subgroup were discussed in plenary meetings. The proposed updates were posted on the EHDN website to be electronically discussed by EHDN members. A revised version will be submitted to IHA and WFNHDRG members for further discussion. The final approval is foreseen at the World Congress on Huntington's Disease in Melbourne, September 2011. Results The following topics were selected for review: testing of minors (Rec 2.), lab standard of accuracy (Rec 2.8), limitation of the test information about age of onset and intermediate/low penetrance alleles (5.2.3, 5.2.4) and discrimination (4.2, 5.3) In addition, new guidelines were proposed, dealing with PGD and information about clinical trials. The proposed updates will be reported at the meeting in Prague as well as the evidence and documents on which they are based. Conclusions The results indicate the need to fill the gap between the present guidelines and the state of the art in research and ethical elaboration. Comments, reactions and suggestions from the EHDN Congress participants are essential for the update validation.
ACCESSION #
66321997

 

Related Articles

  • Predictive testing for Huntington's disease. Harper, Peter S.; Morris, Michael J. // BMJ: British Medical Journal (International Edition);2/18/89, Vol. 298 Issue 6671, p404 

    Examines the progress and problems of predictive testing for Huntington's disease in Great Britain. Discovery of the genetic marker for the disease; Use of markers in predicting a serious and untreatable neurological disease; Determination of the disease through single genetic locus.

  • Refusing to provide a prenatal test: can it ever be ethical? Duncan, Rony E.; Foddy, Bennett; Delatycki, Martin B. // BMJ: British Medical Journal (International Edition);11/18/2006, Vol. 333 Issue 7577, p1066 

    Huntington's disease is an autosomal dominant lethal neurodegenerative disorder, with a mean age of onset of 37 years. There is no treatment that modifies the natural course of the disease. Prenatal genetic testing can raise difficult ethical issues for clinicians. The International Huntington...

  • Genetic testing and counselling.  // Journal of Neurology, Neurosurgery & Psychiatry;Sep2012 Supplement, Vol. 83, pA48 

    The article presents abstracts on genetic testing and counseling in Huntington's disease state which includes prenatal diagnosis for the disease, trinucleotide repeats in genetic diagnosis of the disease and importance of predictive testing to better serve patients.

  • Huntington's disease: psychiatric practice in molecular genetic prediction and diagnosis. Scourfield, Jane; Soldan, Jo; Gray, Jonathon; Houlihan, Gary; Harper, Peter S. // British Journal of Psychiatry;Feb97, Vol. 170, p146 

    Background Predictive genetic testing for Huntingtons disease has been available in Cardiff since 1987 using linked genetic markers, and since 1993 using direct mutation testing, which can also be used as a diagnostic test. During this period there have been numerous referrals that have required...

  • Choreatische Bewegungsst�rungen. Kosinski, C.M.; Landwehrmeyer, B. // Nervenarzt;Sep2007, Vol. 78 Issue 0, p37 

    The differential diagnosis of chorea includes a growing number of rare diseases. This article gives hints on clinical differences and possible laboratory investigations which may help to identify the underlying disease. The majority of hereditary chorea cases are caused by Huntington's disease....

  • Knowing isn't everything. Spaulding, Sally // Newsweek;4/3/1995, Vol. 125 Issue 14, p16 

    Opinion. Describes the progressive debilitating effects of Huntington's disease, an incurable inherited disease which can be detected through genetic testing, and argues that planning for the future with Huntington's is impossible, except for the very wealthy. The author's personal experience...

  • Ethics of a predictive test for Huntington's chorea. Thomas, S. // British Medical Journal (Clinical Research Edition);5/8/1982, Vol. 284 Issue 6326, p1383 

    Investigates the ethics of a predictive test for Huntington's chorea in Great Britain. Pathophysiology of Huntington's chorea; Effects of genetic counselling on patients; Discussion of predictive testing.

  • Genetic testing for Huntington's disease. Harper, Peter S.; Morris, Michael J.; Tyler, Audrey // BMJ: British Medical Journal (International Edition);4/28/90, Vol. 300 Issue 6732, p1089 

    Focuses on the gene mapping for Huntington's disease in Great Britain. Formulation of international guidelines on gene testing; Importance of skilled counselling; Developments in the predicative testing for Huntington's disease.

  • DNA ANALYSIS IN GENETIC DISORDERS. Kingston, Helen M. // BMJ: British Medical Journal (International Edition);7/15/89, Vol. 298 Issue 6692, p170 

    Focuses on the impact of DNA analysis on the understanding of genetic disorders. Reason for the examination of hemoglobinopathies at a molecular DNA level; Possibility of the detection of carriers of cystic fibrosis in the population through DNA analysis; Performance of predictive DNA testing...

  • Molecular medicine: predicting and preventing Huntington’s disease. Squitieri, Ferdinando; Cannella, Milena; Frati, Luigi // Neurological Sciences;Sep2008, Vol. 29 Issue 4, p205 

    The article reports on the diagnosis and treatment of Huntington's disease (HD). The Huntington's disease can be diagnosed by molecular genetic tests before the appearance of its first symptoms. Its potential biomarkers depend on pathogenic mechanisms and can be identified by cross-sectional...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics